Evaluation of the Radioprotective Effect of Famotidine Against Radiotherapy- induced Acute Toxicity in Patients with Prostate Cancer

ABSTRACT: Interventions: Oral Famotidine 40mg is administrated daily for 2 months twice per day before 2 months Radiotherapy: Once 4 hours before and the other 3 hours before daily Radiotherapy. A Physician determines Bowel & Urinary Toxicities Grade for the patients every week during the treatment by interviewing and blood cell counts are collected biweekly. Primary outcome(s): Gastrointestinal Acute Toxicity as assessed using the RTOG Grading Criteria[every week during the treatment and one month after end of the treatment];Genitourinary Acute Toxicity as assessed using the RTOG Grading Criteria[every week during the treatment and one month after end of the treatment] Study Design: Purpose: Prevention; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;Type of endpoint: Efficacy

DISEASE(S): Renal And Urogenital-normal Development And Function Of Male And Female Renal And Urogenital System,Bowel Toxicity,Urinary Toxicity,Prostate Cancer,Oral And Gastrointestinal-normal Oral And Gastrointestinal Development And Function,Cancer-prostate

PROVIDER: 2457821 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR